Cite
HARVARD Citation
Van Assche, G. et al. (2006). Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut. 55 (11), pp. 1568-1574. [Online].